Bluesky Explorer

#NRSNW

Latest posts tagged with #NRSNW on Bluesky

Trending

#World Baseball Classic #Rachel Maddow #Trump and Cuba #Vaccine Policy #DLSS 5 #Oscars #Strait of Hormuz #Sonic Racing #Ukraine Conflict #MJF Tribute #World Baseball Classic #Rachel Maddow #Trump and Cuba #Vaccine Policy #DLSS 5 #Oscars #Strait of Hormuz #Sonic Racing #Ukraine Conflict #MJF Tribute

Posts tagged #NRSNW

@stocktitan.net

11 hours ago

Preview

JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity The Journal of the American Medical Association publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2 b trial in ALS, including slower functional decline, reduced risk of ALS-related complications, and modulation of disease-relevant biomarkers. CAMBRIDGE, Mass., March 16, 2026/ PRNewswire/-- NeuroSense...

#NRSN #NRSNW JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

www.stocktitan.net/news/NRSN/jama-neurology...

0 0 0 0

@stocktitan.net

1 week ago

Preview

PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference NeuroSense (NASDAQ: NRSN) will present long-term survival data from the Phase 2b PARADIGM trial of PrimeC at the MDA Clinical & Scientific Conference on March 9, 2026. The analysis showed a 65% reduction in risk of death (HR 0.35; p=0.0037) and a >14-month median survival benefit (36.3 vs. 21.4 months; log-rank p=0.0218).The randomized, double-blind, placebo-controlled study enrolled 68 participants (2:1 randomization) with a six-month double-blind period followed by an open-label extension; safety was described as favorable.

#NRSN #NRSNW PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference

www.stocktitan.net/news/NRSN/prime-c-long-t...

0 0 0 0

@stocktitan.net

2 months ago

Preview

World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB NeuroSense (NASDAQ: NRSN) announced that Prof. Steven E. Arnold, a noted Alzheimer's expert and Professor of Neurology at Harvard Medical School, has joined its Scientific Advisory Board.The company said Prof. Arnold brings biomarker-driven clinical development and translational neuroscience experience as NeuroSense advances its PrimeC programs in ALS and Alzheimer's disease. NeuroSense reported that its proof-of-concept Alzheimer's study (RoAD) showed a favorable safety and tolerability profile, and that clinical and biomarker outcomes from RoAD are expected in Q1 2026.

#NRSN #NRSNW World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB

www.stocktitan.net/news/NRSN/world-renowned...

0 0 0 0

@stocktitan.net

3 months ago

#NRSN #NRSNW NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026

www.stocktitan.net/news/NRSN/neuro-sense-to...

0 0 0 0